Under construction – not a live service
Sign in
Taking people in AustraliaPhase 2

PRA-216 for Moderate to Severe Atopic Dermatitis

Tests PRA-216 against a placebo in adults with moderate to severe atopic dermatitis.

Plain-language title generated from the registry record
Registry title: PRA-216 Atopic Dermatitis Safety and Efficacy Study

Key facts

Where
Botany, Camberwell, Coorparoo, Liverpool, and Melbourne, AustraliaSee the 5 sites
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults aged 18 to 70 with moderate to severe atopic dermatitis who did not respond well enough to creams or ointments put on the skin.

Age
18 to 70 years
Sex
All sexes can join.
Disease stage
Moderate to severe atopic dermatitis (AD), with a documented diagnosis before enrollment.
Earlier treatment
People must have had an inadequate response to topical medications for AD. Antibody therapy within 4 months or 5 half-lives is not allowed. Other investigational agents within 30 days or 5 half-lives are not allowed.

Main reasons for not taking part

  • Another clinically significant skin condition besides AD
  • Any physical or psychological condition that prevents finishing the study
  • Illicit drug use or alcoholism within 12 months before the first dose
  • History of severe allergic reactions or hypersensitivity
  • Antibody therapy within 4 months or 5 half-lives

Read by machine on 9 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Source: NCT07810777, who can take part

Where in Australia

  • Emeritus - SydneyBotany, AustraliaTaking people
  • Emeritus - MelbourneCamberwell, AustraliaNot yet recruiting
  • Cornerstone Centre for Clinical ResearchCoorparoo, AustraliaTaking people
  • Aperio Clinical ResearchLiverpool, AustraliaNot yet recruiting
  • Momentum SunshineMelbourne, AustraliaNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Prana Therapies Inc
Trial code
NCT07810777
Record updated
28 October 2026
Original description
This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)Read full original descriptionShow less

A Phase 2 Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Multi-Center Study to Evaluate the Safety and Efficacy of PRA-216 in Participants With Moderate to Severe Atopic Dermatitis

This study will evaluate the safety, tolerability, pharmacokinetics and immunogenicity of PRA-216 compared to placebo in patients with moderate to severe Atopic Dermatitis (AD)

Inclusion: Must be in good health with no significant medical history; Willing and able to attend all study visits, comply with study requirements; Able and willing to provide written informed consent; Documented AD diagnosis prior to enrollment; History of inadequate response to topical medications for AD.

Exclusion: Known history of illicit drug use or alcoholism within 12 months prior to the first dose of study agent; Receipt of antibody therapy within 4 months or 5 half-lives; Other investigational agent(s) within 30 days or 5 half-lives; Evidence of clinically significant skin condition or disease other than AD; Any physical or psychological condition that prohibits study completion; History of severe allergic reactions or hypersensitivity.

ClinicalTrials.gov NCT07810777